X

Trial Profile

Phase II Open-Label Study of Weekly Taxoprexin (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DHA-paclitaxel (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors American Regent; Luitpold Pharmaceuticals

Most Recent Events

14 Jan 2009 Actual completion date reported as April 2007 by ClinicalTrials.gov.
14 Jan 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
24 Aug 2007 The expected completion date for this trial is now 1 Apr 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com